BPC-157

Gastrointestinal Protection

Multiple preclinical studies demonstrate protective effects against NSAID damage, alcohol, stress ulceration, and inflammatory bowel disease models. In IBD models, BPC-157 accelerated mucosal healing, reduced TNF-α, IL-1β, and IL-6, and restored barrier integrity.³²

Tendon and Ligament Repair

In rat Achilles tendon models, BPC-157 increased biomechanical strength, organized collagen deposition, and improved tendon-to-bone integration. Similar effects in ligament injury models. One mechanistic finding: the peptide upregulated growth hormone receptor expression in tendon fibroblasts.⁴²

Peripheral Nerve Injury

In sciatic nerve crush models, BPC-157 enhanced functional recovery, improved nerve conduction velocities, and accelerated architectural restoration. The neuroprotective effects coordinated with improved microvascular coupling between nerve and capillary beds.⁵¹

Early Clinical Evidence (2021-2025)

A small but growing body of pilot studies has emerged:

• Interstitial Cystitis (2024): 12 women received intravesical 10mg BPC-157. 10/12 achieved complete resolution, 2/12 showed 80% improvement. No adverse events. PubMed
• IV Safety (2025): 2 healthy adults received 10-20mg IV over 1 hour. No adverse effects on cardiac, hepatic, renal, or glucose biomarkers. PubMed
• Knee Pain (2021): 17 patients received 4mg intra-articular injection. 91.6% reported significant improvement. Retrospective, no control group. PubMed

Systematic Reviews

A 2025 HSS Journal systematic review screened 544 articles and included 36 (35 preclinical, 1 clinical), concluding that due to lack of high-quality clinical evidence, use should be approached with caution. A separate 2025 narrative review identified theoretical safety concerns including pathologic angiogenesis potential.⁹¹⁰

BPC-157 has a robust preclinical evidence base. Human clinical data remain limited to small pilot studies (~28 subjects total across published reports).

No large-scale controlled human trials have been published. The mechanisms have been characterized in cell culture and animal studies. A 2019 systematic review concluded that while preclinical safety profiles appear favorable, rigorous clinical trials are needed to establish human safety and efficacy.²

For laboratory research use only.

1. Sikiric P et al. "BPC 157 and standard angiogenic growth factors." Curr Pharm Des. 2018;24(18):1972-1989. PubMed
2. Gwyer D et al. "Pentadecapeptide BPC-157: a systematic review." J Complement Integr Med. 2019;16(3). PubMed
3. Seiwerth S et al. "BPC 157's effect on healing." J Physiol Pharmacol. 2018;69(4). PubMed
4. Kang EA et al. "BPC 157 in tendon and ligament injuries." J Orthop Surg Res. 2018;13(1):142. PubMed
5. Cesarec V et al. "Pentadecapeptide BPC 157 and the central nervous system." Neural Regen Res. 2013;8(4):366-370. PubMed
6. Bui DT et al. "Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis." Altern Ther Health Med. 2024. PubMed
7. Bui DT et al. "Safety of Intravenous Infusion of BPC157 in Humans." Altern Ther Health Med. 2025. PubMed
8. Bui DT et al. "Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain." Altern Ther Health Med. 2021. PubMed
9. Ghanem S et al. "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review." HSS J. 2025. PubMed
10. Katzman BM et al. "Regeneration or Risk? A Narrative Review of BPC-157." Curr Rev Musculoskelet Med. 2025. PubMed